Epigenomics and breast cancer

Pang Kuo Lo, Saraswati Sukumar

Research output: Contribution to journalArticle

Abstract

Breast carcinogenesis involves genetic and epigenetic alterations that cause aberrant gene function. Recent progress in the knowledge of epigenomics has had a profound impact on the understanding of mechanisms leading to breast cancer, and consequently the development of new strategies for diagnosis and treatment of breast cancer. Epigenetic regulation has been known to involve three mutually interacting events - DNA methylation, histone modifications and nucleosomal remodeling. These processes modulate chromatin structure to form euchromatin or heterochromatin, and in turn activate or silence gene expression. Alteration in expression of key genes through aberrant epigenetic regulation in breast cells can lead to initiation, promotion and maintenance of carcinogenesis, and is even implicated in the generation of drug resistance. We currently review known roles of the epigenetic machinery in the development and recurrence of breast cancer. Furthermore, we highlight the significance of epigenetic alterations as predictive biomarkers and as new targets of anticancer therapy.

Original languageEnglish (US)
Pages (from-to)1879-1902
Number of pages24
JournalPharmacogenomics
Volume9
Issue number12
DOIs
StatePublished - Dec 2008

Fingerprint

Epigenomics
Breast Neoplasms
Carcinogenesis
Breast
Histone Code
Euchromatin
Gene Expression
Heterochromatin
DNA Methylation
Drug Resistance
Chromatin
Biomarkers
Maintenance
Recurrence
Genes

Keywords

  • breast cancer
  • CpG islands
  • demethylating agents
  • DNA methylation
  • epigenetics
  • histone deacetylase inhibitors
  • histone modifications
  • nucleosomal remodeling

ASJC Scopus subject areas

  • Pharmacology
  • Genetics
  • Molecular Medicine

Cite this

Epigenomics and breast cancer. / Lo, Pang Kuo; Sukumar, Saraswati.

In: Pharmacogenomics, Vol. 9, No. 12, 12.2008, p. 1879-1902.

Research output: Contribution to journalArticle

Lo, Pang Kuo ; Sukumar, Saraswati. / Epigenomics and breast cancer. In: Pharmacogenomics. 2008 ; Vol. 9, No. 12. pp. 1879-1902.
@article{f2b598252b634205aa150eb0ba7a0411,
title = "Epigenomics and breast cancer",
abstract = "Breast carcinogenesis involves genetic and epigenetic alterations that cause aberrant gene function. Recent progress in the knowledge of epigenomics has had a profound impact on the understanding of mechanisms leading to breast cancer, and consequently the development of new strategies for diagnosis and treatment of breast cancer. Epigenetic regulation has been known to involve three mutually interacting events - DNA methylation, histone modifications and nucleosomal remodeling. These processes modulate chromatin structure to form euchromatin or heterochromatin, and in turn activate or silence gene expression. Alteration in expression of key genes through aberrant epigenetic regulation in breast cells can lead to initiation, promotion and maintenance of carcinogenesis, and is even implicated in the generation of drug resistance. We currently review known roles of the epigenetic machinery in the development and recurrence of breast cancer. Furthermore, we highlight the significance of epigenetic alterations as predictive biomarkers and as new targets of anticancer therapy.",
keywords = "breast cancer, CpG islands, demethylating agents, DNA methylation, epigenetics, histone deacetylase inhibitors, histone modifications, nucleosomal remodeling",
author = "Lo, {Pang Kuo} and Saraswati Sukumar",
year = "2008",
month = "12",
doi = "10.2217/14622416.9.12.1879",
language = "English (US)",
volume = "9",
pages = "1879--1902",
journal = "Pharmacogenomics",
issn = "1462-2416",
publisher = "Future Medicine Ltd.",
number = "12",

}

TY - JOUR

T1 - Epigenomics and breast cancer

AU - Lo, Pang Kuo

AU - Sukumar, Saraswati

PY - 2008/12

Y1 - 2008/12

N2 - Breast carcinogenesis involves genetic and epigenetic alterations that cause aberrant gene function. Recent progress in the knowledge of epigenomics has had a profound impact on the understanding of mechanisms leading to breast cancer, and consequently the development of new strategies for diagnosis and treatment of breast cancer. Epigenetic regulation has been known to involve three mutually interacting events - DNA methylation, histone modifications and nucleosomal remodeling. These processes modulate chromatin structure to form euchromatin or heterochromatin, and in turn activate or silence gene expression. Alteration in expression of key genes through aberrant epigenetic regulation in breast cells can lead to initiation, promotion and maintenance of carcinogenesis, and is even implicated in the generation of drug resistance. We currently review known roles of the epigenetic machinery in the development and recurrence of breast cancer. Furthermore, we highlight the significance of epigenetic alterations as predictive biomarkers and as new targets of anticancer therapy.

AB - Breast carcinogenesis involves genetic and epigenetic alterations that cause aberrant gene function. Recent progress in the knowledge of epigenomics has had a profound impact on the understanding of mechanisms leading to breast cancer, and consequently the development of new strategies for diagnosis and treatment of breast cancer. Epigenetic regulation has been known to involve three mutually interacting events - DNA methylation, histone modifications and nucleosomal remodeling. These processes modulate chromatin structure to form euchromatin or heterochromatin, and in turn activate or silence gene expression. Alteration in expression of key genes through aberrant epigenetic regulation in breast cells can lead to initiation, promotion and maintenance of carcinogenesis, and is even implicated in the generation of drug resistance. We currently review known roles of the epigenetic machinery in the development and recurrence of breast cancer. Furthermore, we highlight the significance of epigenetic alterations as predictive biomarkers and as new targets of anticancer therapy.

KW - breast cancer

KW - CpG islands

KW - demethylating agents

KW - DNA methylation

KW - epigenetics

KW - histone deacetylase inhibitors

KW - histone modifications

KW - nucleosomal remodeling

UR - http://www.scopus.com/inward/record.url?scp=61549112191&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=61549112191&partnerID=8YFLogxK

U2 - 10.2217/14622416.9.12.1879

DO - 10.2217/14622416.9.12.1879

M3 - Article

VL - 9

SP - 1879

EP - 1902

JO - Pharmacogenomics

JF - Pharmacogenomics

SN - 1462-2416

IS - 12

ER -